Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349114 · ClinicalTrials.gov registry record · Phase 4
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01349114 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 21 participants.
The verdict
NCT01349114, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The study will evaluate the effects of the direct renin inhibitor, aliskiren, on flow-mediated dilation of the brachial artery and on central aortic pressure in diabetic patients with pre-hypertension or Stage 1 hypertension.
Interventions
- DRUG aliskiren 300 mg once daily
- DRUG Placebo/sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349114
The ClinicalTrials.gov registry entry for NCT01349114 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aliskiren 300 mg once daily is the first listed.
NCT01349114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349114 about?
NCT01349114 is a clinical study titled "Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects". The study will evaluate the effects of the direct renin inhibitor, aliskiren, on flow-mediated dilation of the brachial artery and on central aortic pressure in diabetic patients with pre-hypertension or Stage 1 hypertension.
What is the current status of trial NCT01349114?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2011-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01349114?
The interventions under investigation include: aliskiren 300 mg once daily (DRUG), Placebo/sugar pill (DRUG).
Who is sponsoring clinical trial NCT01349114?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.